Clinical Trial

MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2023 (before its estimated September 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observation study is to test in patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • Effect of MAGIC algorithm probability guided preemption of aGVHD with ruxolitinib on prevention of severe aGVHD. Participants will take ruxolitinib with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days. Researchers will compare patients who don't receive preemption of aGVHD with ruxolitinib to see if there is an improvement in severe aGVHD.
Trial Details
NCT Number NCT06075225
Lead Sponsor Sichuan University
Conditions GVHD, Acute Stem Cell Transplant Complications
Enrollment 62 participants
Start Date 2023-10-01
Primary Completion 2024-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-10-10